Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD of Vitro Biopharma, Inc. from Q3 2021 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Vitro Biopharma, Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and change rate from Q3 2021 to Q2 2025.
  • Vitro Biopharma, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 31 Jul 2025 was $175K, a 88.7% decline year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $175K -$1.37M -88.7% 31 Jul 2025 10-Q 12 Sep 2025
Q1 2025 $198K -$1.47M -88.1% 30 Apr 2025 10-Q 20 Jun 2025
Q4 2024 $114K -$1.77M -94% 31 Jan 2025 10-Q 20 Mar 2025
Q3 2024 $571K +$470K +462% 31 Oct 2024 10-Q 12 Sep 2025
Q2 2024 $1.54M +$1.26M +441% 31 Jul 2024 10-Q 12 Sep 2025
Q1 2024 $1.66M +$1.41M +561% 30 Apr 2024 10-Q 20 Jun 2025
Q4 2023 $1.88M +$1.7M +939% 31 Jan 2024 10-Q 20 Mar 2025
Q3 2023 $102K -$640K -86.3% 31 Oct 2023 10-Q 12 Sep 2025
Q2 2023 $285K -$1.41M -83.1% 31 Jul 2023 10-Q 16 Sep 2024
Q1 2023 $252K -$1.97M -88.7% 30 Apr 2023 10-Q 31 May 2024
Q4 2022 $181K -$3.05M -94.4% 31 Jan 2023 10-Q 14 Mar 2024
Q3 2022 $742K -$3.64M -83.1% 31 Oct 2022 10-K 28 Jan 2025
Q2 2022 $1.69M 31 Jul 2022 10-Q 28 Aug 2023
Q1 2022 $2.22M 30 Apr 2022 10-Q 13 Jun 2023
Q4 2021 $3.23M 31 Jan 2022 10-Q 14 Mar 2023
Q3 2021 $4.38M 31 Oct 2021 10-K 29 Jan 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.